tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Novartis upgraded to Equal Weight from Underweight at Morgan Stanley

Morgan Stanley upgraded Novartis (NVS) to Equal Weight from Underweight with a price target of $123, up from $110. The firm believes the company’s valuation for growth is more attractive than Roche. Novartis’ growth is now higher quality with less from Cosentyx, which is going off-patent in 2029, and its execution could continue to surprise to the upside, the analyst tells investors in a research note.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Read More on NVS:

Disclaimer & DisclosureReport an Issue

1